Record growth masks margin miss; semiconductor, new molecules unlock multi-year upside

Revenue +42.9% YoY, but EBITDA margin 19.3% vs prior 20-22% guidance

ES revenue down 52% QoQ to ₹63M due to Middle East raw material crisis; full-year ₹40-60Cr guidance still held

First batch produced at plant scale, successfully qualified by customer; validates R&D but no revenue yet (validation/scaling path 3-4 years)

One molecule commenced production Q1; expect ₹70-80Cr FY27, ₹200Cr at full scale; achieves milestone

Raw material supply disruption cost ES 2 months; prices rose sharply; cost pass-through lag compressed margins

Prior call: 20-22% margins for FY27. Q1 delivered 19.3% due to cost inflation + supply crisis. Management did NOT lower full-year target, maintaining 20-22% for FY27 contingent on cost pass-through execution. No numeric cut; holding line.

Transcript reveals 2-month production loss from Middle East raw material shortage. ES down ₹40M+ QoQ. Not in prior guidance; external shock, not demand miss. ₹40-60Cr FY27 guidance unchanged.

Prior call: pipeline milestone. Q1 call: first plant-scale batch delivered and customer-qualified. Validates manufacturing capability and quality systems. Long-term game-changer but 3-4 years to real volume.

One pharma intermediate production commenced Q1 (vs prior guideline Q1 target). ₹70-80Cr incremental FY27 contribution confirmed, ₹200Cr full scale. Validation of R&D-to-commercialization pipeline.

Continuous flow MONOGLYME equipment installed but plan to scale capacity abandoned. Chinese price collapse ($4.6→$2.1 in 30 days) made it uneconomical. Equipment repurposed for supercapacitor electrolyte. Strategic pivot, not core guidance.

Prior: 25-30% FY27 growth. Q1 delivered 42.9% YoY. Management said will maintain 25-30% run rate for full year (i.e., slower growth in Q2-Q4 vs Q1). No change to guidance, just tempering expectations after strong start.

PTC demand widening due to acceptability across chemical industry. Forward integration into SDA and ES means less external PTC sales as those segments scale, but long-term PTC loyalty customers will be served. Organic growth continues.

Converted MONOGLYME equipment to supercapacitor electrolyte due to Chinese price collapse ($4.6→$2.1 in 30 days). Continue conventional glymes at small scale; pharma industry is main customer, not battery makers. Withheld expansion capex.

None foreseen. All customer demand quite visible, segments are clear. No obstacles to guidance target.

₹70-80 Cr FY27. At full utilization, ₹200 Cr range.

Product used as key starting block for semiconductor manufacturing (most stringent spec), also for PCB etching and cleaning. TAM too early to gauge but 'very large potential.' 3-4 plant-scale trials planned over 2 years; commercialization path 3+ years. Long-term opportunity.

Multipurpose, multiproduct facility fungible across sectors. Targets scaling R&D-ready products and domestic demand. Aims ₹300 Cr revenue at 1.2-1.5x asset turnover. 18-21 month timeline (internally pushing 18 months).

Sticking to ₹40-60Cr guidance. Capacity in place; lost 2 months due to Middle East raw material shortage impacting Q1. Customer demand crystal clear, visibility high. No special efforts needed; everything in place.

Marginally pricing. Genuinely volume growth. Cost inflation passed through slowly; now pushing price increases (last 40-50 days). Value chain cost inflation is real; pricing still catching up.

Debottlenecking possible but won't address growth beyond ₹800-850Cr. Dahej nearly saturated; very small block feasible. Need Jolva facility within 18-21 months to avoid stagnation.

Expected Jan 2026 (pending confirmation). Specialty chemicals/agro/pharma subsidy removal could benefit Tatva. Too early to predict; awaiting policy clarity.

No lithium batteries. Zinc battery solutions, supercapacitor battery solutions only. No lithium exposure.

Euro 7 Europe-only now; will roll to US, Japan, China, India over 3-5 years. Chinese diesel truck demand weak (shift to gas/EV). European diesel still strong; that's the real demand for SDA. Euro 7 removes prior geographic sales limits; will expand market share.

Hybrid customer commercialization begins Oct-Nov 2026. Full-scale ramp late 2027. Major ES demand from stationary energy storage customers (immediate). Hybrid is future growth lever.

2 products currently using continuous flow. 7-8 products in near-term pipeline will have electrochemistry or continuous flow. Continuous flow is core focus for productivity, cost, yield improvements.

If Tatva can do it, others can too. Requires dedication, vision, focus, investment over time. Conventional is faster/easier; continuous flow needs patience. No impenetrable moat, but first-mover advantage.

Both. Converting existing products batch→continuous to free reactor capacity. 8 near-term R&D products also have continuous flow stages. Mix of both.

No formal contracts. Some informal customer commitments that 'yes, we are interested; if you can crack this in a different way, we are first to buy.'

Over next 3-4 years, 20-25% compounded growth year-on-year visible.

Equipment installed; repurposed for supercapacitor electrolyte due to Chinese price collapse (fell from $4.6-4.8 to $2.1 in 30 days). Producing few hundred tons conventional glymes only. Continuous flow equipment repurposed for different product.

Still uneconomical. Directly tied to polymer industry, which hasn't recovered. No commercialization in near future.

5 products total. One plant-scale (just qualified). One pilot-scale (customer evaluating). 3 in development. All in early/mid-stage qualification.

9 mature pipeline products (excluding long-term semiconductor products; those won't commercialize pre-2028).

Q1 delivered 42.9% YoY. Management said will maintain 25-30% run rate for full year, implying slower QoQ growth ahead vs. strong Q1 start.

Q1 only ₹6.3Cr despite 76% YoY growth. Raw material supply crisis caused 2-month production loss. Guidance reaffirmed but no order book mentioned; quarter-on-quarter basis.

One molecule commenced production Q1. Two more expected by Q3. Demand described as clear and repeating; customers moving from initial commercialization to recurring orders.

Based on 1.2-1.5x asset turnover ratio. Facility multipurpose, fungible across segments. 18-21 month commissioning timeline; no committed customer volumes at close of call.

Q1 delivered 19.3%, below target. Management acknowledged losing 1 quarter to cost inflation and slow pass-through lag. Reaffirmed full-year target pending price increases (started 40-50 days before call). Risk if inflation continues or pass-through stalls.

Q1 NPM 9.4%, compressed from typical 10-12% due to EBITDA miss. Not explicitly guided on call.

Board approved. Groundbreaking July 20, 2026. Multipurpose facility targeting ₹300Cr peak revenue. 18-21 month operational timeline (internally 18-month push).

Middle East crisis caused 2-month ES production delay and ₹40M+ revenue loss in Q1. Chinese pricing collapse ($4.6→$2.1 in 30 days for glymes) deferred capacity expansion. Geopolitical events create abrupt supply/demand shocks.

EBITDA margin 19.3% Q1 vs 20-22% guided. Cost inflation was 'too rampant' and came at 'short notice'; management slow to pass through until 40-50 days before call. If inflation accelerates or customers resist price hikes, margin target at risk.

₹200Cr greenfield Jolva facility critical to growth beyond ₹850Cr revenue. 18-21 month timeline aggressive; any delay throttles FY28-29 growth. Commissioning risk for multipurpose, fungible facility (design complexity).

First plant-scale batch qualified Q1, but only 'few tons' delivered. Path to commercialization: 3-4 more plant-scale trials (2 years), then volume scaling. Real revenue not expected pre-Q4 2028. Customer validation process 'extremely difficult,' per management. No revenue risk near-term, but long-term opportunity TAM unquantified.

₹40-60Cr FY27 guidance represents 6-10x Q1 (₹6.3Cr). Major lever is hybrid battery customer commercialization Oct-Nov 2026, but full-scale ramp expected late 2027—delayed one year from call. Stationary energy storage demand 'quite visible' but not quantified. Risk if demand slips or timelines pushed further.

Management concedes competitors can replicate continuous flow chemistry if they dedicate resources. No impenetrable moat; first-mover advantage transient (3-5 years?). Ongoing R&D investment required to stay ahead.